Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate

Margot, N; Cox, S; Das, M; McCallister, S; Miller, MD; Callebaut, C

Margot, N (reprint author), Gilead Sci Inc, Foster City, CA 94404 USA.

ANTIVIRAL THERAPY, 2017; 22 (5): 443

Abstract

Background: Tenofovir alafenamide (TAF) is a novel prodrug of the nucleotide reverse transcriptase inhibitor tenofovir (TFV) that loads lymphocytes wi......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索